Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asasantin Retard vs Aspirin in Aspirin-Resistant CAD
NCT00129038Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2004
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dipyridamole in coronary artery disease (CAD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Platelet aggregation in response to arachidonic acid at day 30. Started Apr 2004; status: completed.
02
Drugs
dipyridamole
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00129038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129038.